查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2058145

周邊T細胞淋巴瘤（PTCL）：新型療法、未滿足的需求與TPP洞察報告，2026年

Peripheral T-Cell Lymphoma (PTCL) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 53 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 法國PTCL市場預計將從2,100萬美元成長到3,200萬美元，反映出市場溫和擴張。
  • 市場成長受以下因素驅動：
  • 採用標靶治療和抗體藥物複合體
  • 增加移植和二線治療策略的使用
  • 雖然患者人數不多，但昂貴的治療方法和密集的治療方法支撐了市場規模。
  • 表觀遺傳療法和新型免疫腫瘤藥物的持續創新有望塑造未來的市場動態。
  • 未來的成長取決於開發出治療復發或難治性疾病患者的有效治療方法，並提高患者的存活率。

周邊T細胞淋巴瘤（PTCL）的新治療方法及對TPP的深入了解

Thelansis 發布的《外周 T 細胞淋巴瘤（PTCL）：新型療法、未滿足的需求和 TPP 洞察報告，2026》全面分析了該適應症的關鍵新興治療方法和主要藥物發現機會，包括新興的競爭格局、未滿足的需求、目標產品概況（TPP）、試驗設計和關鍵意見領袖（KOL）的見解。

周邊T細胞淋巴瘤（PTCL）概述

周邊T細胞淋巴瘤（PTCL）是一組罕見、高度異質且極具侵襲性的成熟T細胞和自然殺手（NK）細胞腫瘤，約佔所有非何傑金氏淋巴瘤的10-15%。此疾病包含幾種生物特性不同的亞型，其中最常見的是PTCL-NOS（非其他類型的周邊T細胞淋巴瘤）、血管免疫母細胞性T細胞淋巴瘤（AITL）和間變性大細胞淋巴瘤（ALCL）。這些亞型分別由表觀遺傳學改變、T細胞受體訊號傳導異常和致癌性突變所引起。

臨床上，周邊T細胞淋巴瘤（PTCL）的特徵是疾病進展迅速、淋巴結廣泛腫大、全身性B細胞症狀（發燒、盜汗、體重減輕）以及常見的結外病變，包括皮膚、骨髓和肝臟的病變。此病病程通常具有侵襲性，預後較B細胞淋巴瘤差。

傳統上，以CHOP方案為基礎的第一線化療療效不佳，且由於內源性化療抗藥性，復發率較高。隨後，治療模式不斷發展，特別是隨著分子標靶治療的引進。對於CD30陽性亞型（尤其是間變性大細胞淋巴瘤），布倫妥昔單抗合併化療（BV-CHP）是建議的第一線治療方案。

對於已達到緩解的符合條件患者，自體周邊血幹細胞移植（ASCT）通常用於維持治療。對於復發或難治性病例，則採用新型分子標靶治療，包括組蛋白去乙醯化酶（HDAC）抑制劑和抗葉酸藥物（如普拉曲沙）。儘管取得了這些進展，但治療效果仍然有限，凸顯了對更有效、更持久的治療方法的迫切需求。

主要亮點

  • 在法國，預計新診斷的PTCL 病例數將從 1448 例增加到 1981 例，這表明該疾病對患者群體帶來的負擔日益加重。
  • 雖然 PTCL 仍然很罕見，但它是一種高度侵襲性的淋巴瘤亞型，與 B 細胞淋巴瘤相比，其預後較差。
  • 由於對傳統化療有其固有抗藥性，復發率居高不下。
  • 治療模式轉向標靶治療（例如，brentoximab vedotin）和精準醫療方法。
  • 復發/難治性 PTCL 的治療和長期疾病控制方面存在著巨大的未滿足需求。

透過對醫生和關鍵意見領袖（KOL）的調查所獲得的見解：

  • 透過對關鍵意見領袖（KOL）的訪談，獲得了更深入的見解，進一步豐富了研究成果。
  • 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

  • PowerPoint簡報
  • MS Excel

主要問題

  • 詳細的競爭格局趨勢
  • 管道分析
  • 符合新興治療方法的患者
  • 主要企業
  • 主要作用機制
  • 發布日期等的預測
  • 臨床試驗趨勢分析
  • 目標患者群
  • 試驗終點
  • 測試設計
  • 受試者招募標準等。
  • 未滿足的需求和機會
  • 目前主要治療方法的有效性
  • 未滿足需求的關鍵領域
  • 估算主要未滿足需求的市場規模
  • 目標產品概況
  • 屬性和級別
  • 醫生開立的處方
  • 預期患者佔有率
  • 關鍵KOL洞察對領先新興治療方法的見解
  • 意識
  • 預期用途/處理線
  • 對主要未滿足需求的滿意度
  • KOL評論

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

主要企業

  • Xenothera SAS
  • Dizal Pharmaceuticals
  • Chipscreen Biosciences, Ltd.
  • Boryung Pharmaceutical Co., Ltd
  • SecuraBio
  • Acrotech Biopharma Inc.
  • Boston Immune Technologies and Therapeutics
  • Corvus Pharmaceuticals, Inc.
  • SciTech Development, Inc.
  • Aileron Therapeutics, Inc.
  • AstraZeneca
  • Kymera Therapeutics, Inc.
  • Bio-Path Holdings, Inc.
  • Pfizer

目錄

第1章 主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 領先的新興治療方法 - 概述和KOL洞察

第3章 產品屬性分析

  • 重點
  • 科學屬性
  • 商業性屬性
  • 產品定位

第4章 一級市場調查

  • 目前治療狀態
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療環境
  • 當前挑戰
  • 未滿足的需求
  • 新興治療方法
  • 主要治療方法和目標患者群
  • 主要特點和優勢
  • 未來治療前景
  • 未滿足的需求和關鍵意見領袖的期望

第5章 未滿足的需求和TPP分析

  • 新興治療方法的主要未滿足需求和未來成就
  • TPP分析與KOL預期

第6章 監理與償付環境

第7章 附錄

簡介目錄

Peripheral T-Cell Lymphoma (PTCL) Emerging Therapy and TPP Insights

Thelansis's "Peripheral T-Cell Lymphoma (PTCL) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Peripheral T-Cell Lymphoma (PTCL) Overview

Peripheral T-cell lymphoma (PTCL) represents a rare, heterogeneous, and highly aggressive group of mature T-cell and natural killer (NK)-cell neoplasms, accounting for approximately 10-15% of all non-Hodgkin lymphomas. The disease comprises multiple biologically distinct subtypes, most commonly PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large cell lymphoma (ALCL), each driven by epigenetic alterations, aberrant T-cell receptor signaling, and oncogenic mutations.

Clinically, PTCL is characterized by rapid disease progression, presenting with generalized lymphadenopathy, systemic B symptoms (fever, night sweats, weight loss), and frequent extranodal involvement, including the skin, bone marrow, and liver. The disease course is typically aggressive, with poor prognosis compared to B-cell lymphomas.

Historically, frontline treatment with CHOP-based chemotherapy resulted in suboptimal outcomes and high relapse rates due to intrinsic chemoresistance. The treatment paradigm has since evolved, particularly with the incorporation of targeted therapies. For CD30-positive subtypes (notably ALCL), the combination of brentuximab vedotin with chemotherapy (BV-CHP) has become a preferred frontline regimen.

Consolidation with autologous stem cell transplantation (ASCT) is commonly pursued in eligible patients achieving remission. In the relapsed/refractory setting, treatment relies on novel targeted agents, including histone deacetylase (HDAC) inhibitors and antifolate therapies such as pralatrexate. Despite these advances, outcomes remain limited, underscoring a significant unmet need for more effective and durable therapies.

Key Highlights

  • In France, diagnosed incident PTCL cases are projected to increase from 1,448 to 1,981, indicating a rising disease burden.
  • PTCL remains a rare but highly aggressive lymphoma subtype with poor prognosis compared to B-cell lymphomas.
  • High relapse rates persist due to intrinsic resistance to conventional chemotherapy.
  • Treatment paradigm is shifting toward targeted therapies (e.g., brentuximab vedotin) and precision medicine approaches.
  • Significant unmet need exists in relapsed/refractory PTCL and long-term disease control.

Market Overview

  • The France PTCL market is projected to grow from $21M to $32M, reflecting moderate market expansion.
  • Market growth is driven by:
  • Adoption of targeted therapies and antibody-drug conjugates
  • Increasing use of transplant and second-line treatment strategies
  • Despite low patient numbers, market value is supported by high-cost therapies and intensive treatment approaches.
  • Continued innovation in epigenetic therapies and novel immuno-oncology agents is expected to shape future market dynamics.
  • Future growth will depend on effective therapies for relapsed/refractory patients and improved survival outcomes.

Insights driven by surveys with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs
  • Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
  • Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
  • Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
  • KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Xenothera SAS
  • Dizal Pharmaceuticals
  • Chipscreen Biosciences, Ltd.
  • Boryung Pharmaceutical Co., Ltd
  • SecuraBio
  • Acrotech Biopharma Inc.
  • Boston Immune Technologies and Therapeutics
  • Corvus Pharmaceuticals, Inc.
  • SciTech Development, Inc.
  • Aileron Therapeutics, Inc.
  • AstraZeneca
  • Kymera Therapeutics, Inc.
  • Bio-Path Holdings, Inc.
  • Pfizer

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

  • Key takeaways
  • Scientific attributes
  • Commercial attributes
  • Product positioning

4. Primary Market Research

  • Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
  • Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)